For laboratory research use only. Not for human or animal use or consumption.

CJC-1295, Ipamorelin, and Sermorelin appear frequently in discussions of growth hormone signaling, but they are not interchangeable research compounds.

The central distinction is their receptor target. CJC-1295 and Sermorelin belong to the growth hormone–releasing hormone (GHRH) analog family. Ipamorelin acts through the ghrelin receptor, also known as the growth hormone secretagogue receptor. Another essential distinction is molecular identity: material described as “CJC-1295 without DAC” must not be treated as equivalent to the albumin-binding CJC-1295 investigated in long-acting pharmacology studies. [1–4]

This comparison examines those differences, explains how to interpret the evidence, and identifies documentation relevant to laboratory research. For background terminology, see What Are Research Peptides?.

What are GH secretagogues?

A secretagogue is a substance that stimulates secretion. In this context, GH secretagogues are compounds investigated for their ability to stimulate growth hormone release in responsive experimental systems.

The terminology requires care. “GH secretagogue” can serve as a broad functional description, while “growth hormone secretagogue receptor” refers specifically to the ghrelin receptor pathway. Compounds that influence GH release do not necessarily activate that receptor.

This produces two relevant groups:

• GHRH analogs: Sermorelin and CJC-related compounds.
• Ghrelin receptor agonists: Ipamorelin.

Neither group is growth hormone itself. A receptor-mediated secretory response is also different from a direct measurement of compound stability, receptor binding, or downstream biological activity. [1–4]

CJC-1295 vs Ipamorelin vs Sermorelin at a glance

Research characteristic	CJC-1295 / CJC-related materials	Ipamorelin	Sermorelin
Compound family	Modified GHRH analogs	Synthetic pentapeptide; ghrelin mimetic	GHRH(1–29) amide
Principal receptor pathway	GHRH receptor	Ghrelin receptor, GHS-R1a	GHRH receptor
Key identity distinction	DAC-containing and no-DAC materials must be distinguished	Sequence, stereochemistry, and salt form	Amidated 29-residue sequence and salt form
Evidence emphasis	Molecular modification, albumin binding, and endocrine signaling	Receptor pharmacology and experimental selectivity	GHRH fragment biology and historical pharmacology
Main comparison limitation	Long-acting CJC findings do not automatically apply to no-DAC materials	Selectivity does not establish general safety or absence of other effects	Historical drug evidence does not validate research-grade products

The table compares scientific categories, not suitability for medical use. [1–5]

What distinguishes CJC-1295 with DAC from CJC-1295 without DAC?

“CJC-1295” is not a sufficiently precise description on its own.

The long-acting compound investigated in prominent published studies contains an albumin-binding modification associated with the term Drug Affinity Complex, or DAC. Material sold as CJC-1295 without DAC is commonly described as Modified GRF(1–29), a modified 29-residue GHRH analog without that albumin-binding component.

FDA’s 2024 advisory materials distinguish several CJC-related substances, including DAC-containing forms and different salts. This reinforces the need to identify the exact substance rather than rely on a familiar catalog name. [1]

Why does this matter when reading research?

A study of an albumin-binding compound cannot automatically establish the persistence, activity, or safety profile of a no-DAC material.

Teichman and colleagues investigated a long-acting CJC-1295 preparation in controlled human studies. That paper is relevant to the tested molecule and study conditions; it is not evidence that every product labeled “CJC-1295” has the same properties. [2]

A separate study by Ionescu and Frohman reported preserved GH pulsatility during long-acting CJC-1295 exposure, alongside increased trough GH levels. Therefore, “pulsatility was preserved” should not be rewritten as “the baseline endocrine pattern was unchanged.” [3] PubMed

For related background, see What Is CJC-1295 + Ipamorelin?.

How does Ipamorelin differ?

Ipamorelin is a synthetic pentapeptide associated with ghrelin receptor activation. It belongs to a different receptor class from Sermorelin and GHRH analogs.

The National Cancer Institute’s Ipamorelin entry identifies it as a ghrelin mimetic and notes that the receptor occurs in multiple tissues. Consequently, the description “GH secretagogue” does not mean the compound’s biology is confined to one pituitary endpoint. [4]

What does the original selectivity study actually show?

Raun and colleagues’ 1998 study included laboratory and animal experiments. In the swine experiments, Ipamorelin did not produce ACTH or cortisol responses significantly different from those observed with GHRH stimulation, whereas GHRP-2 and GHRP-6 increased those hormones.

That is a specific experimental finding. It does not establish that Ipamorelin never influences other hormones or has no adverse effects.

The prolactin finding also deserves precision: none of the tested secretagogues affected prolactin in that experiment. The paper therefore does not support claiming that Ipamorelin uniquely avoided prolactin stimulation while every comparator increased it. [5] pubmed.ncbi.nlm.nih.gov

What distinguishes Sermorelin?

Sermorelin corresponds to the amidated 1–29 fragment of human GHRH. It is structurally related to the endogenous signaling molecule and belongs to the GHRH receptor agonist family.

Research on GHRH fragments and modified sequences helps explain why molecular details matter: changes to amino-acid identity, stereochemistry, and terminal chemistry can alter experimental activity. Published structure–activity research on GHRH(1–29)-related analogs illustrates this point. [6]

For additional background, see What Is Sermorelin?.

Does Sermorelin’s regulatory history apply to research products?

Sermorelin-containing Geref products have a historical FDA approval record. In 2013, FDA determined that the specified discontinued Geref products had not been withdrawn for reasons of safety or effectiveness.

That determination concerns those drug products. It does not confer FDA approval on research-grade Sermorelin, another supplier’s formulation, or a different intended use. [7] govinfo.gov

Why can half-life comparisons be misleading?

A half-life number is meaningful only when the substance, biological system, sampling method, and experimental conditions are identified.

Several different measurements are often blurred together:

• Plasma half-life: decline of the measured compound in circulation.
• Assay stability: persistence under specific laboratory conditions.
• Pharmacodynamic duration: persistence of a measured biological response.
• Storage stability: maintenance of material quality during storage.

These are different questions. A plasma half-life is not an instruction for laboratory storage, and it does not establish how long a downstream signal will remain detectable.

Published Ipamorelin pharmacokinetic work and long-acting CJC-1295 studies provide examples of compound-specific investigation. Their findings should remain attached to their original experimental context. [2,8]

Does targeting two receptors prove a combination is better?

No. Different receptor targets provide a reason to investigate combined activity; they do not establish superiority.

For a laboratory comparison, useful controls may include each component separately, the combination, a vehicle control, and appropriate receptor-specific controls. Without those comparisons, an observed response cannot reliably be assigned to one component or described as synergy.

A larger response from a mixture is not, by itself, proof of synergy. That conclusion requires an explicit model of the expected combined response and suitable experimental data.

Likewise, literature about individual compounds does not establish that a commercial mixture has equivalent identity, stability, or biological activity.

What documentation should researchers review?

Analytical documentation should support the exact material and batch used in the experiment.

Relevant information includes:

• Compound identity, sequence, terminal modifications, and salt form.
• Explicit DAC status for CJC-related materials.
• Lot number and a clear connection between the report and supplied material.
• Analytical methods, dates, and laboratory identification.
• Chromatographic results and appropriate identity testing.
• Component-specific identification and quantification for mixtures, where required.

Purity, identity, and quantity are separate measurements. A chromatographic area percentage does not automatically establish peptide content by mass, sterility, endotoxin status, or suitability for human use.

For more detail, read HPLC vs. LC-MS: Understanding Peptide Purity and Identity Testing and Peptide Certificate of Analysis: How to Read a COA.

Related Peptides Exchange research materials

The following catalog links provide product information for laboratory materials:

• CJC-1295 without DAC 10 mg + Ipamorelin 10 mg — a multi-component research formulation.
• Ipamorelin — a standalone research material.
• Available Certificates of Analysis — published analytical reports for review.

Confirm current specifications and matching batch documentation directly. Inclusion in this article does not establish equivalence to materials used in published studies, regulatory approval, or suitability for human or animal use.

What does research use only mean here?

This article discusses molecular identity, receptor biology, analytical characterization, and interpretation of published evidence. References to historical human or animal studies describe the literature; they do not authorize those uses for Peptides Exchange materials.

FDA has identified safety concerns and evidence limitations involving compounded CJC-1295 and Ipamorelin products. Receptor selectivity, a high purity result, or the existence of a published study should not be interpreted as proof of human safety. [9]

Research-use-only wording also does not override evidence of a different intended use. FDA warning letters demonstrate that website claims can establish human-drug intent despite research disclaimers. [10]

Peptides Exchange materials are intended strictly for in-vitro laboratory research by qualified professionals. They are not intended for human or animal use, consumption, diagnosis, treatment, cure, or prevention of disease.

Frequently asked questions

Are CJC-1295 and Ipamorelin the same peptide?

No. CJC-related GHRH analogs and Ipamorelin belong to different molecular and receptor classes.

Are CJC-1295 without DAC and long-acting CJC-1295 interchangeable?

No. The albumin-binding modification is a material chemical distinction. Evidence should be matched to the precise substance studied.

Is Sermorelin growth hormone?

No. Sermorelin is a GHRH fragment analog. It is distinct from growth hormone itself.

Does selective GH release mean Ipamorelin is proven safe?

No. Selectivity describes particular experimental observations. It does not establish overall safety.

Which compound is best for research?

There is no universal ranking. The relevant choice depends on the receptor question, experimental model, exact molecular identity, analytical documentation, and controls.

Sources and further reading

1. FDA. December 2024 Pharmacy Compounding Advisory Committee briefing materials. CJC-related substance identities and regulatory evaluation context. The packet includes both FDA analysis and submitted nomination materials.
2. Teichman SL, et al. Long-acting CJC-1295 pharmacology in healthy adults. Journal of Clinical Endocrinology & Metabolism. 2006. DOI: 10.1210/jc.2005-1536.
3. Ionescu M, Frohman LA. GH pulsatility during long-acting CJC-1295 stimulation. Journal of Clinical Endocrinology & Metabolism. 2006. DOI: 10.1210/jc.2006-1702.
4. National Cancer Institute. Ipamorelin: NCI Drug Dictionary. Molecular and receptor classification.
5. Raun K, et al. Original Ipamorelin selectivity study. European Journal of Endocrinology. 1998. DOI: 10.1530/eje.0.1390552.
6. Primary structure–activity research. GHRH(1–29)-NH₂ analog studies. Experimental investigation of sequence modifications and biological activity.
7. FDA / Federal Register. 2013 determination concerning discontinued Geref products. Product-specific regulatory history.
8. Primary pharmacokinetic research. Ipamorelin pharmacokinetic–pharmacodynamic modeling. Pharmaceutical Research. 1999.
9. FDA. Bulk drug substances that may present significant safety risks. Includes CJC-1295 and Ipamorelin safety concerns.
10. FDA. Gram Peptides warning letter, March 31, 2026. Illustrates why research disclaimers do not override evidence of intended human use.